The IHC results of subcutaneous tumors demonstrated that synergistic therapy significantly decreased the expression of the tumor proliferation marker (Ki-67) and the immune checkpoints (PD-1 and PD-L1) but significantly promoted the expression of CD8A, suggesting that synergistic therapy could effectively inhibit tumor proliferation, induce the infiltration of CD8+ T cells and reverse the tumor immune escape (Figure 10F; Figure S10A, B). This evidence concerns the gene PDCD1 and neoplasm.